These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 33728771)

  • 1. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.
    Yoshida H; Kim YH; Ozasa H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Yamamoto T; Ajimizu H; Hirai T
    In Vivo; 2018; 32(6):1587-1590. PubMed ID: 30348720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
    Dong X; Fernandez-Salas E; Li E; Wang S
    Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
    Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
    JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.
    Berberich A; Schmitt LM; Pusch S; Hielscher T; Rübmann P; Hucke N; Latzer P; Heßling B; Lemke D; Kessler T; Platten M; Wick W
    J Neurooncol; 2020 Jan; 146(1):9-23. PubMed ID: 31776900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer.
    Yoshida R; Sasaki T; Minami Y; Hibino Y; Okumura S; Sado M; Miyokawa N; Hayashi S; Kitada M; Ohsaki Y
    Int J Oncol; 2017 Nov; 51(5):1533-1540. PubMed ID: 29048652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
    Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
    Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
    Furugaki K; Harada N; Yoshimura Y
    Anticancer Drugs; 2022 Feb; 33(2):124-131. PubMed ID: 34520436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
    Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
    Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
    Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
    Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.